Oral DNA vaccines containing SL3261 that target the vascular endothelial growth factor receptor-3 (VEGFR-3) extracellular domains have shown efficacy in treating melanoma, colon cancer, lung cancer and breast cancer. Here, FLT4 is linked to breast carcinoma.